These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The challenge of assuring continued post-trial access to beneficial treatment. Grady C Yale J Health Policy Law Ethics; 2005; 5(1):425-35. PubMed ID: 15742586 [No Abstract] [Full Text] [Related]
3. Free to Choose: A Moral Defense of the Right-to-Try Movement. Brodrick M J Med Philos; 2020 Jan; 45(1):61-85. PubMed ID: 31922578 [TBL] [Abstract][Full Text] [Related]
4. Ethical responsibility of phase 0 trials. Arai RJ; Hoff PM; de Castro G; Stern A Clin Cancer Res; 2009 Feb; 15(3):1121; author reply 1121-2. PubMed ID: 19188189 [No Abstract] [Full Text] [Related]
5. For-profit clinical trials in developing countries--those troublesome patient benefits. Schuklenk U Am J Bioeth; 2010 Jun; 10(6):52-4. PubMed ID: 20526975 [No Abstract] [Full Text] [Related]
6. Increasing access to investigational drugs. Christian M Clin Adv Hematol Oncol; 2004 Feb; 2(2):90-1. PubMed ID: 16163167 [No Abstract] [Full Text] [Related]
7. American society of clinical oncology - 45th annual meeting. Part 1. Gale S IDrugs; 2009 Jul; 12(7):401-3. PubMed ID: 19579154 [No Abstract] [Full Text] [Related]
8. American society of clinical oncology - 45th annual meeting. Part 2. Lakeram M; Kibble A IDrugs; 2009 Jul; 12(7):404-8. PubMed ID: 19579155 [No Abstract] [Full Text] [Related]
9. "Right to Try" Laws: The Gap between Experts and Advocates. Dresser R Hastings Cent Rep; 2015; 45(3):9-10. PubMed ID: 25944200 [No Abstract] [Full Text] [Related]
10. Administrative gatekeeping - a third way between unrestricted patient advocacy and bedside rationing. Lauridsen S Bioethics; 2009 Jun; 23(5):311-20. PubMed ID: 18410460 [TBL] [Abstract][Full Text] [Related]
11. When too much is just enough: what do oncologists tell parents? Berg SL Pediatr Blood Cancer; 2009 Apr; 52(4):437-8. PubMed ID: 19058206 [No Abstract] [Full Text] [Related]
12. Professional integrity and screening tests. Doukas DJ Am J Bioeth; 2009 Apr; 9(4):19-21. PubMed ID: 19326304 [No Abstract] [Full Text] [Related]
13. Gatekeeping access to community mental health teams: a qualitative study. McEvoy P; Richards D Int J Nurs Stud; 2007 Mar; 44(3):387-95. PubMed ID: 16843468 [TBL] [Abstract][Full Text] [Related]
14. Oncologists' knowledge, attitudes and practices related to cancer treatment clinical trials. Kaanoi M; Braun KL; Gotay CC; Abrigo L Hawaii Med J; 2002 May; 61(5):91-5. PubMed ID: 12073745 [TBL] [Abstract][Full Text] [Related]
15. Access to 'investigational' cancer drugs: perspective of a trainee. Kuo JC Intern Med J; 2015 Feb; 45(2):235. PubMed ID: 25650544 [No Abstract] [Full Text] [Related]
16. "I Think It's Been Met With a Shrug:" Oncologists' Views Toward and Experiences With Right-to-Try. Smith C; Stout J; Adjei AA; Buckner J; Wentworth M; Tilburt J; Master Z J Natl Cancer Inst; 2021 Jun; 113(6):735-741. PubMed ID: 32882030 [TBL] [Abstract][Full Text] [Related]
17. Dilemmas in the compassionate supply of investigational cancer drugs. Lewis JR; Lipworth W; Kerridge I; Doran E Intern Med J; 2014 Sep; 44(9):841-5. PubMed ID: 25201421 [TBL] [Abstract][Full Text] [Related]
18. Response to open peer commentaries on "A broader view of justice". Jecker NS Am J Bioeth; 2008 Oct; 8(10):W1-2. PubMed ID: 19003691 [No Abstract] [Full Text] [Related]
19. Targeted drugs take centre stage at US cancer meeting. McCarthy M Lancet; 2001 May; 357(9268):1593. PubMed ID: 11377652 [No Abstract] [Full Text] [Related]
20. Demand grows for early access to promising cancer drugs. Baldwin J J Natl Cancer Inst; 2002 Nov; 94(22):1668-70. PubMed ID: 12441318 [No Abstract] [Full Text] [Related] [Next] [New Search]